We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Noninvasive Procedure Improves Success Rate of IVF

By LabMedica International staff writers
Posted on 19 Nov 2008
A safe, simple, noninvasive procedure provides an objective measure of embryo viability, and when used as an adjunct to morphology, helps clinicians identify embryos of highest reproductive potential for in vitro fertilization (IVF). More...


Called the ViaMetrics-E procedure, it uses a highly sensitive method of metabolomic analysis by near infrared (NIR) spectroscopy, the can be performed on-site in just minutes, requiring only a small amount of spent culture media.

The procedure promises to be revolutionary for the millions of people worldwide who are affected by infertility. The technology fulfills an unmet medical need and it is well positioned to tap into the US$4 billion global IVF market. Further, the technology may hold significant potential to increase IVF success rates, while minimizing the number IVF cycles required to achieve a live birth. ViaMetrics-E could also provide physicians with a procedure that will reduce the incidence, costs, and medical risks associated with multiple births, which constitute more than one-third of births under current IVF methods.

ViaMetrics-E was developed by the metabolomics company, Molecular Biometrics (Chester, NJ, USA). Safeguard Scientifics (Wayne, PA, USA), a holding company that provides growth capital for entrepreneurial and innovative technology and life sciences companies, has announced it co-led a $12 million Series A financing round with Oxford Bioscience Partners (OBP; Boston, MA, USA), a venture capital firm, for Molecular Biometrics. Molecular Biometrics will use the financing to support ongoing R&D for ViaMetrics-E and to launch the patented technology in Europe, Japan, and Australia sometime in 2009.

James A. Datin, executive vice president and managing director of the Life Sciences Group at Safeguard commented, "Safeguard partners with entrepreneurial life sciences companies who have differentiated products and a competitive advantage in markets that represent sizable opportunities. We look for strong management teams that address key strategic themes throughout our target markets--molecular and point-of-care diagnostics, medical devices or specialty pharmaceuticals--and are on a solid trajectory towards global commercialization.”

Related Links:
Molecular Biometrics
Safeguard Scientifics
Oxford Bioscience Partners


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: New findings show unique pathogen‑directed antibody patterns are already present years ahead of a formal diagnosis of inflammatory bowel disease (Image Credit: iStock)

Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.